•
-
Planetary Health
Biology Without Cells: The Rise of Cell-Free Biomanufacturing
Cell-free systems are redefining what’s possible in bioproduction. By bypassing the complexity of living cells, innovators can run enzyme cascades, prototype metabolic pathways, and produce high-value molecules with unmatched speed, precision, and purity. This new class of systems—from freeze-dried reactions to continuous cell-free reactors—enables rapid iteration, on-demand production, and scalable biochemistry without the need for fermentation tanks or long development cycles.
Featuring
Amy Locks
Anzen Industries
CEO
Enzyme-stabilization expert building cell-free modular “enzyme reactors.”
Jonathan Weinstein
Scala Biodesign
Prin. Scientist, Protein Design Alg. & AI
Christopher Pirie
Decycle Bio
CEO
De-novo, cell-free enzyme cascades converting waste into chemicals
Neeka Mashouf
Rubi Laboratories
CEO and Co-founder
Cynthia Collins
Ginkgo Bioworks
GM, Ginkgo Reagents
Kavya Sharman
Phase Capital
Managing Partner
•
-
Planetary Health
Biology Without Cells: The Rise of Cell-Free Biomanufacturing
Cell-free systems are redefining what’s possible in bioproduction. By bypassing the complexity of living cells, innovators can run enzyme cascades, prototype metabolic pathways, and produce high-value molecules with unmatched speed, precision, and purity. This new class of systems—from freeze-dried reactions to continuous cell-free reactors—enables rapid iteration, on-demand production, and scalable biochemistry without the need for fermentation tanks or long development cycles.
Featuring
Amy Locks
Anzen Industries
CEO
Enzyme-stabilization expert building cell-free modular “enzyme reactors.”
Jonathan Weinstein
Scala Biodesign
Prin. Scientist, Protein Design Alg. & AI
Christopher Pirie
Decycle Bio
CEO
De-novo, cell-free enzyme cascades converting waste into chemicals
Neeka Mashouf
Rubi Laboratories
CEO and Co-founder
Cynthia Collins
Ginkgo Bioworks
GM, Ginkgo Reagents
Kavya Sharman
Phase Capital
Managing Partner
SynBioBeta is where the people building with biology meet the people funding, buying, and partnering with them. If you're raising capital, scouting the next wave of AIxBIO companies, or looking for your next technology partner - the people you need are here for three days.
The startups on stage this year are building programmable RNA medicines, virtual cell models, AI-designed enzymes, and proteins that replace sugar - alongside GSK, Sanofi, Novo Nordisk, Eli Lilly, J&J, Mars, Apple, Google, NVIDIA, Unilever, and P&G.
Watching where the partnerships form and which technologies the biggest players are actually evaluating is something you can't get from a report or a webinar. And our 1:1 Partnering App lets you book meetings before you arrive.
“SynBioBeta is a who’s who of AI and biology.
This is where the future is being built, so don't miss it”
“SynBioBeta is a who’s who of AI and biology.
This is where the future is being built, so don't miss it”
Eric Schmidt
Former CEO
"For every single fund at Boom Capital, one of our best companies has come directly from SynBioBeta. I met Mammoth Bio at SynBioBeta, and I met Nabla Bio at SynBioBeta."
Celestine Schnugg
Founder
"Nabla was accelerated into existence because of SynBioBeta. I met Seth Bannon from 50 Years, Cee Cee Schnugg from Boom Capital, and others from Y Combinator there, and those same people seeded Nabla. The vibe, leverage, and energy at SynBioBeta are unreal."
"Nabla was accelerated into existence because of SynBioBeta. I met Seth Bannon from 50 Years, Cee Cee Schnugg from Boom Capital, and others from Y Combinator there, and those same people seeded Nabla. The vibe, leverage, and energy at SynBioBeta are unreal."
Surge Biswas
Founder
"Our Series A came together because of a little bit of SynBioBeta magic. I’ve been attending for a decade and it’s been inspiring to watch the field evolve from a lot of hopes and dreams to real products and applications."
"Our Series A came together because of a little bit of SynBioBeta magic. I’ve been attending for a decade and it’s been inspiring to watch the field evolve from a lot of hopes and dreams to real products and applications."
Jacob Glanville
Founder & CEO
"I met Algen at SynBioBeta and later invested in the company. It’s exactly the kind of connection that makes the community so valuable."
"I met Algen at SynBioBeta and later invested in the company. It’s exactly the kind of connection that makes the community so valuable."
Bill Tai
Co-founder
"At SynBioBeta I met the team at Biomatter, an AI-driven enzyme design company. The environment made it easy to start a real conversation. That conversation turned into a collaboration to improve one of our enzymes. We're now exploring entirely new performance possibilities together."
"At SynBioBeta I met the team at Biomatter, an AI-driven enzyme design company. The environment made it easy to start a real conversation. That conversation turned into a collaboration to improve one of our enzymes. We're now exploring entirely new performance possibilities together."
Luis Cascao-Pereira
Head of Digital Biology
"Every time I attend SynBioBeta, I walk away with something transformative – a new investor, a fantastic hire, or an idea that changes how we work. It’s a community unlike any other."
"Every time I attend SynBioBeta, I walk away with something transformative – a new investor, a fantastic hire, or an idea that changes how we work. It’s a community unlike any other."
Ola Wlodek
CEO
